NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition
SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ('NKGen' or the 'Company'), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will be speaking at the 7th China International Biotechnology Conference & Exhibition (BIOTEC-CHINA 2025), to be held in Beijing, China, April 16-18, 2025.
BIOTEC-CHINA 2025 is a premier gathering of biotechnology and pharmaceutical professionals from across the globe. With close to 1,500 attendees, the event offers a unique opportunity for intensive networking, collaboration, and the exploration of promising new partnerships. Covering a broad range of life science research and applications, BIOTEC-CHINA 2025 will spotlight key innovation areas such as drug discovery, biomanufacturing, genomics, nanotechnology, and cell therapy.
NKGen Presentation Details:
Title:
Use of Autologous Enhanced Natural Killer Cells for Alzheimer's and Parkinson's Disease
Location:
Shuijing Hall, Beijing Huanghe Jingdu Conference Center, The Third Building
Date and Time:
April 17, 2025, at 10:20 am – 10:40 am CST (China Standard Time) UTC/GMT +8
Dr. Song will present on the use of troculeucel in the treatment of patients with Alzheimer's and Parkinson's disease, highlighting the promising results previously observed in our Phase 1 clinical trials and compassionate use cases. Additionally, Dr. Song will provide an update on NKGen's ongoing Phase 1/2a clinical trial for moderate Alzheimer's disease, with recent data presented at the AD/PD™ 2025 conference. The favorable clinical outcomes and biomarker data disclosed to date offer strong indications that troculeucel may emerge as a viable treatment option for patients with Alzheimer's and Parkinson's disease.
Previously disclosed data for troculeucel in Alzheimer's disease can be found on the Scientific Publications page of the Company's website at https://nkgenbiotech.com/scientific-publications/. News releases containing troculeucel clinical trial updates and regulatory approvals can be found on the News page of the Company's website at https://nkgenbiotech.com/news/.
About TroculeucelTroculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name ('INN') for SNK01 assigned by the World Health Organization ('WHO'). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market.
About NKGen BiotechNKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.
Forward-Looking Statements Statements contained in this press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'could', 'continue', 'expect', 'estimate', 'may', 'plan', 'outlook', 'future' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption 'Risk Factors' and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website at www.sec.gov and on the Company's website under the subheading 'Investors—Financial and Filings'. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Internal Contact:Denise Chua, MBA, CLS, MLS (ASCP)SVP, Corporate Affairs949-396-6830dchua@nkgenbiotech.com
External Contact:Kevin GardnerManaging DirectorLifeSci Advisors, LLCkgardner@lifesciadvisors.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
28 minutes ago
- Business Insider
Ord Minnett Remains a Buy on Telstra Corporation Limited (TTRAF)
Ord Minnett analyst maintained a Buy rating on Telstra Corporation Limited (TTRAF – Research Report) today and set a price target of A$5.00. The company's shares closed last Thursday at $3.15. Confident Investing Starts Here: In addition to Ord Minnett, Telstra Corporation Limited also received a Buy from Morgan Stanley's Andrew McLeod in a report issued on May 28. However, on the same day, UBS downgraded Telstra Corporation Limited (Other OTC: TTRAF) to a Hold. The company has a one-year high of $3.45 and a one-year low of $2.19. Currently, Telstra Corporation Limited has an average volume of 29.92K. Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TTRAF in relation to earlier this year.
Yahoo
2 hours ago
- Yahoo
SOMA GOLD INTERSECTS VENUS GAP VEIN AT DEPTH WITH 7.5 g/t Au OVER 6.0 m, EXTENDING ZONE BY 135 m
Highlights include the following drill intercepts: RVICDDH-24-032 1.7 m at 9.2g/t Au incl. 0.6 m at 18.8g/t Au RVICDDH-24-034 2.1 m at 11.9g/t Au incl. 0.65 m at 32.5g/t Au RVICDDH-24-040 6.0 m at 7.5g/t Au incl. 0.65 m at 9.3g/t Au and 0.5m at 67.8g/t Au VANCOUVER, BC, June 11, 2025 /CNW/ - Soma Gold Corp. (TSXV: SOMA) (WKN: A2P4DU) (OTC: SMAGF) (the "Company" or "Soma") is pleased to announce ongoing drill results targeting the "Venus Gap" zone of the Cordero Mine on the Bagre Project in central Colombia (Figure 1). Twelve diamond drill holes, totaling 2,848 meters of underground drilling, were designed to test the dip extent of the Venus Gap Zone (see Figures 2 and 3). The drilling results outlined in this press release extend the dip of the vein by approximately 135 meters downdip. The Cordero Deposit is hosted in the El Carmen Stock and consists of coarse-grained tonalite, diorite, and gabbroic phases. The quartz veins form as laminated fault-fill veins within a sinistral brittle-ductile shear zone. They are interpreted as conjugate shears within a steeply dipping, north-striking regional shear zone. The controlling shear zone also hosts the Los Mangos Deposit, located 2.8 kilometres to the north. The quartz veins in the Cordero Deposit form a series of en echelon segments that consistently step to the right along strike. The veins have been repeatedly reactivated and exhibit three distinct phases of development: early barren quartz veins, sphalerite + galena + pyrite + gold mineralization controlled by microfractures, and brittle fracturing along the margins of the veins filled with quartz + pyrite + tellurides + gold. Gold mineralization occurs during the latter two phases of vein development. The final stage of brittle fracturing and micro-breccia is commonly associated with 'bonanza' gold grades. Subsequently, the veins are crosscut by aphanitic mafic dykes and numerous brittle faults. The brittle faults are generally dextral and offset the quartz veins from <1.0m to 10s of metres. The late brittle faults commonly dismember the mineralized veins into short strike-length segments, the continuity of which is difficult to discern from drill data. The Cordero Deposit is informally divided into five main zones: Athenas, Cordero, Venus, Venus Gap, and Victoria Ramp zones (Figure 2). Table 1: Composited assay results from the lower Venus Gap ZoneTable 1 Composited assay results from Lower Venus Gap Zone Hole ID From (m) To (m) Length (m) Au (g/t) Ag (g/t) RVICDDH-24-030 158.8 160.3 1.5 6.4 17.7 including 159.7 160.3 0.6 15.9 42.9 RVICDDH-24-031 141.5 143.7 2.2 6.7 8.4 including 141.5 142.3 0.8 7.3 6.9 including 142.3 142.7 0.4 14.9 23.0 RVICDDH-25-032 184 185.65 1.65 9.2 15.7 including 184 184.6 0.6 18.8 30.3 RVICDDH-25-034 154.45 156.55 2.1 11.9 31.8 including 154.45 155.1 0.65 32.5 92.1 RVICDDH-25-035 193 194.7 1.7 3.6 4.7 including 194 194.7 0.7 6.5 7.9 RVICDDH-25-036 204.1 205.1 1 1.4 1.9 RVICDDH-25-037 no significant results RVICDDH-25-038 no significant results RVICDDH-25-039 138.9 140.2 1.3 0.5 1.3 RVICDDH-25-040 176.6 182.6 6 7.5 10.2 including 177.25 177.9 0.65 9.3 21.4 including 180.05 180.55 0.5 67.8 39.7 RVICDDH-25-041 no significant results RVICDDH-25-042 169.4 172 2.6 6.7 9.9 including 171.4 172 0.6 19.5 33.8 Note: all intervals are presented as drilled width. True width is approximately 80%-90% of the drill interval. Soma's Vice President of Exploration, Chris Buchanan, stated, "Drilling in the Venus Gap Zone continues to return the broadest, high-grade intervals in the mine. Extending this zone down dip adds resources to the mine plan and supports development of deeper levels of the Venus and Venus Gap veins." Table 1 presents the composited assay results from twelve drill holes at the Venus Gap Zone. Assays in the drilling range from below detection to a maximum grade of 67.8 g/t Au. The drilling currently covers approximately 150 m of strike length between the southern-most drill intercept (RVICDDH-25-035) and the northern-most intercept (RVICDDH-25-040). RVICDDH-25-036 extends the known dip of the vein system 135m down dip from the 0770 level, the current mining operations. Like other parts of the Venus Gap Zone, wider zones of mineralized stockwork in the footwall of the principal gold-bearing quartz veins and in enclaves of wall rock between anastomosing vein segments were intersected. RIVICDDH-25-040 intersected the widest interval of gold mineralization in the lower Venus Gap with a total width of 6.0 m and an average grade of 7.5 g/t gold (Plate 1). Three of the drill holes intersected quartz veins but did not return significant gold assays (Table 1). This is attributed to the nuggety nature of the gold distribution observed across the Cordero Deposit. A long section of the drill intercepts is presented in Figure 3. The high-grade intercepts delineate multiple segments of the vein system that are separated by cross-cutting faults and late mafic dykes. Selected highlights from the 2024 drill campaign on the upper Venus Gap vein are presented in Table 2 (see news release dated November 12, 2024). Underground drilling is ongoing in this area to determine the strike and dip extents of the lower Venus Gap quartz veins. The vein segments are located proximal to existing mine workings in the Victoria Ramp and Venus Vein areas. Access to the lower Venus Gap is planned from the Victoria Ramp workings and is expected to intersect the veins in Q4 2025. Table 2: Selected highlight intersections from the upperVenus Gap vein (see press release dated November 12, 2024)Hole ID From (m) To (m) Length (m) Au (g/t) BAZUDDH-24-018 52.45 57.65 5.2 16.1 includes 52.45 53.25 0.8 94.3 includes 55.3 55.65 0.35 4.8 RVICDDH-24-018 71.6 73.1 1.5 6.6 includes 71.6 72.6 1 8.8 and 134 135 1 12.5 and 138.4 140.8 2.4 5.4 includes 139.4 140.1 1.4 8.5 and 144.55 145.55 1 2.7 RVICDDH-24-021 46 47 1 3.3 and 76.5 77.5 1 13.7 includes 77.1 77.5 0.4 34.3 and 81.5 82.5 1 11.2 includes 82.1 82.5 0.4 27.6 and 128.2 132.7 4.5 9.3 includes 128.8 129.4 0.6 8.3 includes 130.95 131.8 0.85 27.8 RVICDDH-24-024 71.6 74.6 3 8.9 includes 71.6 72.45 0.85 10 includes 74.2 74.6 0.4 45.1 and 140.4 147.95 7.55 13.9 includes 140.4 141.7 1.3 24.7 includes 146.5 147.95 1.45 48.6 and 151.5 153.3 1.8 4.5 includes 152.3 153.3 1 6.4 VICDDH-23-006 100.1 101.8 1.7 4.1 and 151.15 154.65 3.5 10.7 includes 151.15 151.8 0.65 9 includes 151.8 152.8 1 21.3 includes 152.8 153.65 0.85 10.7 and 158.4 161.2 2.8 1.7Note: Intervals are composited to a 1 m minimum stope width for conventional mining. The drillholes are targeted to intersect the vein orientation as perpendicular as possible. The true width is approximately 70% to 90% of the drilled width. In addition to supporting mining operations at Cordero Mine, Soma's exploration team continues to evaluate numerous small-scale mines near Machuca. Drilling is ongoing at the Colossa and Colossa 2 informal mines (Figure 4). Three high-priority Au anomalies close to informal mines were identified in the regional soil survey. Additionally, the copper anomaly identified on the soil grid is the focus of infill soil sampling and geological mapping. These targets are scheduled for detailed geological mapping and drilling in the second half of 2025. Soma also continues to work with the local communities on the Machuca Property as part of its ongoing ESG program. The Otú fault system ("Otú Fault") extends for over 100 km, from Aris's Segovia-Remedios mines (TSX:ARIS) in the south to Nechi in the north, where it is buried beneath younger sedimentary overlap sequences. Soma's property holdings now cover more than 56 km of this regional structure. High-grade gold mineralization occurs along the entire strike length of the Otú Fault. The high-grade gold occurs in brittle-ductile to brittle quartz veins formed during the later stages of deformation along the Otú Fault. Across the district, the quartz veins typically display orientation patterns that suggest the veins form in conjugate faults associated with brittle faulting on the Otú Fault. Notable deposits along this trend include Segovia-Remedios, La Aurora, El Limon, Le Ye, Los Mangos, and Cordero. The Machuca Property is located along a critical segment of this regional fault structure and displays multiple indications of high-grade gold mineralization. QA/QC Statement Soma follows a comprehensive QA/QC program to ensure the reliability of assay data collected from its exploration programs. All samples are sawn or split in half, with one half being returned to the core box for storage. The second half-core is placed in a labelled plastic bag with a tag, document, and sealed for shipment. Batches of samples are shipped to Actlabs Colombia SAS (Actlabs) in Rio Negro with security tags and documented chain of custody. Pulps of each sample are prepared in Rio Negro. Pulp samples are then shipped to Actlabs Canada for multi-element analysis. All samples are analyzed using package 1E3, an ICP-MS analysis that provides the concentration of 51 elements. Fire assay analysis for gold and Silver is completed by Actlabs in Rio Negro. Thirty-gram aliquots of each sample are analyzed for gold using a standard fire assay with an atomic absorption finish, package 1A2. Overlimit samples are subjected to an additional fire assay with a gravimetric finish, package 1A3-30, to determine the gold concentration. A comprehensive QA/QC program has been implemented to monitor the reliability of assay data collected during exploration programs. The program includes the regular insertion of certified blanks, duplicates, and certified OREAS standards. Assays of the QA/QC samples are automatically compared to the certified value and standard deviations in the database. Qualified Person Statement Mr. Chris Buchanan, is Soma's Vice-President of Exploration and a Qualified Person as defined by National Instrument 43-101. Mr. Buchanan has reviewed the technical information disclosed in this press release. ABOUT SOMA GOLD Soma Gold Corp. (TSXV: SOMA) is a mining company focused on gold production and exploration. The Company owns two adjacent mining properties in Antioquia, Colombia with a combined milling capacity of 675 tpd. (Permitted for 1,400 tpd). The El Bagre Mill is currently operating and producing. Internally generated funds are being used to finance a regional exploration program. With a solid commitment to sustainability and community engagement, Soma Gold Corp. is dedicated to achieving excellence in all aspects of its operations. The Company also owns an exploration property near Tucuma, Para State, Brazil that is currently under option to Ero Copper Corp. On behalf of the Board of Directors "Geoff Hampson"Chief Executive Officer and Chairman Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. All statements, analysis and other information contained in this press release about anticipated future events or results constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking statements are subject to business and economic risks and uncertainties and other factors that could cause actual results of operations to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements. SOURCE Soma Gold Corp. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Meera Syal: When Dad mistook me for Mum, I played along not to upset him
The fact that there isn't even a word in the Punjabi language that means 'dementia' says a lot about the stigma and ignorance surrounding the disease in Indian communities. And yet ironically, incidences of Alzheimer's are much higher in minority ethnicgroups compared to white people. So as a group, we are actually more at risk – and yet we know less. In Asian communities, when signs of memory loss are apparent, it's often just dismissed as old age: 'They're forgetful,' people say. Or 'their minds are going.' But actually there's a huge difference between just age-appropriate forgetfulness and signs of this critical disease. My father, Surendra, really was the most wonderful dad – very loving, playful, sociable, and he adored music. Our house in Walsall, where I grew up, was always full of people singing. Originally a philosophy graduate, Dad worked as an accountant for years in order to provide for our family, my mum Surinder, me and my brother Rajeev, who is seven years younger than me. He was a very bright man who had endured great hardship as a refugee from the partition in 1947, when the British government withdrew from India. Dad's entire family had to abandon their home and flee across the border, so he started from literally nothing and became a self-made man. I'm sure all the stresses he'd suffered going through immigration – and then adaptation – made him more vulnerable to Alzheimer's eventually. It wasn't until 2012 when it became clear to me that Dad wasn't himself. By then I'd long been living in London, as a writer and actor and with two children of my own. Mum had known Dad was unwell for some time, but she had been coping on her own, silently soldiering on for a couple of years before we knew. It started with forgetting where he was driving, the familiar routes he'd taken for years seemed lost. Then in crept a level of paranoia, he became suspicious of even friends he'd known for years. Some days he'd momentarily forget my Mum. Worried, Mum had taken him to the memory clinic several times, but Dad just kept passing the tests, 'maybe because he was having a good day,' she admitted in hindsight. Later, we found out those tests aren't immensely accurate for diagnosing certain different forms of dementia, and actually the only way you can tell is by having a brain scan. In reality, trying to get a brain scan on the NHS is a long and torturous process. You really have to stand your ground and say 'I know something's wrong – and yes he may have passed the memory test – but I know that something is not right.' Ultimately, it was two or three years before Dad's diagnosis was confirmed. That was a long time for my mother to be struggling alone. It must have been isolating. And in that time he could have been taking medication that might have at least been able to help manage his symptoms. Early diagnosis is so crucial. By 2012, Mum could no longer hide it from us or anyone in the wider community. Intervention was needed. Initially we arranged for a carer to come to their home, but that didn't go well as Dad didn't trust them. He didn't want them in the house. And then he kept leaving the house, which meant we had to have security locks fitted to try and keep him safe. He was always restless, and this agitation was hard to live with. Then he became a security risk. One of the cruellest things about this disease is how it affects people's personalities. Becoming ruder or cruder is common with certain types of dementia. Everyone is different so it's impossible to predict. Some people can becalm and vacant, while others become very verbose and front-footed. While Dad was never aggressive, the paranoia was hard, and it was painful when he started insisting Mum had been replaced by a stranger. At that stage we realised we couldn't cope at home, not with Dad escaping, and Mum not being able to keep him safe. For me the worst part was this intermediate stage, when the disease came in and out, because there were times when Dad was completely lucid and cogent and wanted to know what was happening, when he knew something was wrong. This is when families really need support from places like the Alzheimer's Society, because how do you know how to have that conversation with a loved one who is confused and frightened? How do you say the right thing? They have trained, experienced people who can advise you on those difficult talks. What I learnt was that one of the biggest mistakes people make – quite understandably – is trying to correct someone when they are in their own version of reality. Saying to them things like 'No, that's not right' or 'you did that yesterday, remember?' actually distresses a loved one more, because they're coping with two or three different realities in their heads. Instead, it's better to enter into their world with them, even if that means playing along that you are their long-lost friend. Dad would often think I was my mother when she was younger, instead of his daughter. So I'd go along with that as it calmed and reassured him. That has to be the aim. Sometimes, five minutes later after he'd stopped being distressed, he'd find his own way back and know who I was. I came to believe that actually, there are many different kinds of reality in life. I mean, how do we know who's in the right one? Him or me? It becomes quite a Matrix kind of question! I had to open my mind a little bit to try and find the understanding and compassion – and go with whatever he was giving me. When a loved one has dementia it's a long, slow goodbye. You're losing them bit by bit. It's like a little light going off gradually, or a mechanism winding down. You become the parent, not the daughter. While that is certainly awful, there can be many moments of joy along the way, when the light is still on. For Dad, the thing that never left him until the very end, was his passion for music. He loved ghazals, Indian poetry and ballads, which we played and he would sing along. We also put old films from the 1950s and 60s from his youth on the iPad, essentially making our own memory pack for him. Photographs and anything that keeps the memories and the connections going is useful. Dad always had a great sense of humour, so we tried to make him laugh, and be upbeat. Mum visited my dad in the care home every single day and they had a routine, where they'd practise throwing and catching a ball (to keep up his motor skills) and then look at old photos together. You find your own ways of connecting, but the Alzheimer's Society is an amazing resource of information and advice, and through the Dementia Friends network, we found incredible volunteers who would even offer to give relatives a break by sitting and talking to your loved one. Dad was in the care home for six years, so it became the new normal in some ways. You learn to live with the upset, but I hated that in their golden years, when they should have been growing old together, they were separated, with Dad remaining in the home until he died in 2018. When I remember my Papa, I don't try to forget his illness; you can't, it's part of the journey we all had together. I just hope we did everything we could to make his quality of life as good as we could in those last years. You reach a stage where it's actually worse for the family than it is for the person with the disease, because they're in their own world. I took advice about genetic testing, but looking at the rest of my family history, it's highly unlikely to be genetic. There's no history of dementia on my father's side, his older brother is still alive and well, his own father died in his mid-nineties unaffected by dementia. My mother's own mum died at the grand age of 103 (in India!) and she has sisters who are still alive with all their faculties. Losing my parents has made me more health conscious. I'm alert to the increased risks in South Asians of hypertension, obesity, diabetes, and cardiovascular health. And actually there's now more awareness of the massive link between gum disease and Alzheimer's. My father suffered with terrible gums for many, many years. The older I get I take better care of myself, watching my cholesterol levels and cardiovascular health and I regularly exercise and look after my gums with hygienist appointments three times a year. I can't change my genetic hand down, but I can try my best with my lifestyle to try and prevent my kids going through this with me one day. As told to Susanna Galton Meera Syal CBE is an Ambassador for Alzheimer's Society and is supporting the charity's appeal. Donate at Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
